keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis C"

keyword
https://www.readbyqxmd.com/read/27926593/cost-effectiveness-of-direct-acting-anti-viral-treatment-in-hepatitis-c-infected-liver-transplant-candidates-with-compensated-cirrhosis-and-hepatocellular-carcinoma
#1
James Salazar, Varun Saxena, James G Kahn, John P Roberts, Neil Mehta, Michael Volk, Jennifer C Lai
BACKGROUND: HCV(+) donors represent an effective strategy to increase liver donor availability to HCV-infected recipients. However, many HCV(+) transplant candidates are now receiving treatment with direct acting anti-virals (DAA) that lower the risk of posttransplant HCV recurrence but could make the patient ineligible for HCV(+) livers. METHODS: We compared pretransplant DAA treatment versus deferred DAA treatment using a cost-effectiveness decision analysis model to estimate incremental cost-effectiveness ratios (ICERs; cost per quality-adjusted life year [QALY] gained) from the societal perspective across a range of HCV(+) liver availability rates...
December 6, 2016: Transplantation
https://www.readbyqxmd.com/read/27925386/interferon-free-therapies-for-patients-with-chronic%C3%A2-hepatitis-c-genotype-3-infection-a-systematic-review
#2
Vicente Gimeno-Ballester, María Buti, Ramón San Miguel, Mar Riveiro, Rafael Esteban
INTRODUCTION: Treatment of hepatitis C virus (HCV) infection with genotype 3 remains a challenge. The HCV elimination rate with direct acting antivirals (DAAs) is lower than the values reported for other HCV genotypes. In addition, genotype 3 infected patients have a higher risk of disease progression and hepatocellular carcinoma. The aim of this study was to review the relevant literature concerning treatment of HCV genotype 3 patients with interferon-free regimens. MATERIAL AND METHODS: A literature search was conducted in the PubMed/Medline, Embase, and Web of Science electronic databases...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925362/ns5a-inhibitors-for-the-treatment-of-hepatitis-c-infection
#3
Stefano Gitto, Nesrine Gamal, Pietro Andreone
Today, we are witnessing a new era for the treatment of hepatitis C with excellent rates of virologic response and very good safety profiles. Among the many classes of direct acting antivirals, the inhibitors of non-structural protein 5A are particularly interesting. NS5A is phosphorylated protein with a relevant role in viral replication. HCV-NS5A inhibitors show high potency, very good safety profile and high barrier to resistance. The amazing in vitro effectiveness of this class is associated with great efficacy in clinical trials in combination protocols with antivirals of other classes, with sustained virological response (SVR) obtained in more than 90% of patients...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925355/epigenetic-analysis-of-the-ifn%C3%AE-3-gene-identifies-a-novel-marker-for-response-to-therapy-in-hcv-infected-subjects
#4
Jeffrey F Waring, J Wade Davis, Emily Dumas, Daniel Cohen, Kenneth Idler, Stephen Abel, Robert Georgantas, Thomas Podsadecki, Sandeep Dutta
Chronic hepatitis C virus (HCV) infection is characterized by high inter-individual variability in response to pegylated interferon and ribavirin. A genetic polymorphism on chromosome 19 (rs12979860) upstream of interferon-λ-3 (IFNλ3) is associated with a 2-fold change in sustained virologic response rate after 48 weeks of treatment with pegylated interferon/ribavirin in HCV genotype 1 (GT1) treatment-naïve patients. We conducted epigenetic analysis on the IFNλ3 promoter to investigate whether DNA methylation is associated with response to HCV therapy...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925349/hepatitis-c-viremia-reversibly-maintains-subset-of-antigen-specific-t-bet-tissue-like-memory-b-cells
#5
Li-Yuan Chang, Yonghai Li, David E Kaplan
BACKGROUND: Chronic antigen exposure and/or aging increases the frequency of T-box expressed in T cells (T-bet)-expressing B-lymphocytes in mice. The frequency and significance of B-cell T-bet expression during chronic hepatitis C (HCV) infection in human subjects has never been described. METHODS: Healthy controls, cirrhotic and non-cirrhotic HCV-infected patients, and non-HCV patients with cirrhosis were recruited. Peripheral blood mononuclear cells were phenotyped for expression of T-bet and related markers by flow cytometry...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925346/hepatitis-c-infection-and-other-drug-related-harms-among-inpatients-who-injected-drugs-in-turkey
#6
Arash Alaei, Kamiar Alaei, Katherine Waye, Melissa Tracy, Marine Nalbandyan, Elif Mutlu, Mustafa Kemal Cetin
Hepatitis C Virus (HCV) is easily spread among those who share drug injection equipment. Due to the ease of contraction and growing prevalence of HCV in Eastern Europe, the aims of this study focused on describing risky injection practices as well as the prevalence of HCV, HIV, and Hepatitis B Virus (HBV) among people who inject drugs (PWID) that were admitted to public and private drug treatment centers in Turkey from 2012 to 2013. Other aims included identifying correlates of needle sharing and HCV infection...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27924779/hepatic-safety-of-maraviroc-in-patients-with-hiv-1-and-hepatitis-c-and-or-b-virus-144-week-results-from-a-randomized-placebo-controlled-trial
#7
Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda, Jayvant Heera
BACKGROUND: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. METHODS: In this randomised, double-blind, placebo-controlled, multicentre study, patients received maraviroc twice daily (n=70) or placebo (n=67) with concomitant antiretroviral therapy for 144 weeks (clinicaltrials...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27924471/mirna-targeting-drugs-the-next-blockbusters
#8
Marco F Schmidt
Only 20 years after the discovery of small non-coding, single-stranded ribonucleic acids, so-called microRNAs (miRNAs), as post-transcriptional gene regulators, the first miRNA-targeting drug Miravirsen for the treatment of hepatitis C has been successfully tested in clinical Phase II trials. Addressing miRNAs as drug targets may enable the cure, or at least the treatment of diseases, which presently seems impossible. However, due to miRNAs' chemical structure, generation of potential drug molecules with necessary pharmacokinetic properties is still challenging and requires a re-thinking of the drug discovery process...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27924186/treatment-of-chronic-hepatitis-c-infection-with-sofosbuvir-based-regimens-in-a-commercially-insured-patient-population
#9
John Barron, Yiqiong Xie, Sze-Jung Wu, Jeff White, Joseph Singer, Bernard Tulsi, Alan Rosenberg
BACKGROUND: The response to treatment with direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) is not well-characterized in the real-world setting. OBJECTIVE: To describe patients' response to 3 sofosbuvir-based treatment regimens among commercially insured patients with chronic HCV. METHODS: In this observational study, we identified patients with HCV who started sofosbuvir treatment with 1 of 3 sofosbuvir-based regimens between December 1, 2013, and April 30, 2014, in the HealthCore Integrated Research Database, a large managed care repository...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924099/caution-reactivation-of-hepatitis-b-during-hepatitis-c-treatment-with-direct-acting-antiviral-therapy
#10
Anjana A Pillai, Frank A Anania, Brian L Pearlman
No abstract text is available yet for this article.
December 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27923923/antiviral-innate-immune-response-interferes-with-the-formation-of-replication-associated-membrane-structures-induced-by-a-positive-strand-rna-virus
#11
Diede Oudshoorn, Barbara van der Hoeven, Ronald W A L Limpens, Corrine Beugeling, Eric J Snijder, Montserrat Bárcena, Marjolein Kikkert
: Infection with nidoviruses like corona- and arteriviruses induces a reticulovesicular network of interconnected endoplasmic reticulum (ER)-derived double-membrane vesicles (DMVs) and other membrane structures. This network is thought to accommodate the viral replication machinery and protect it from innate immune detection. We hypothesized that the innate immune response has tools to counteract the formation of these virus-induced replication organelles in order to inhibit virus replication...
December 6, 2016: MBio
https://www.readbyqxmd.com/read/27923769/recombination-in-hepatitis-c-virus-is-not-uncommon-among-people-who-inject-drugs-in-kolkata-india
#12
Debanjali Gupta, Kallol Saha, Aritra Biswas, Rushna Firdaus, Monika Ghosh, Provash Chandra Sadhukhan
Recombination in RNA virus is a rare event in the survival and evolution to evade host immune system. This is increasing within high risk group population (HRG) due to super infection that occurs by continuous sharing of common drug equipment by HCV infected or HIV-HCV co-infected recurrent drug users. Recombination causes impediment to vaccine development and therapeutic intervention as standard HCV treatment is still genotype specific. Blood samples of 194 people who inject drugs (PWID) were collected from an Opioid Substitution Therapy Centre in Kolkata,India...
December 3, 2016: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/27923693/post-treatment-resistance-analysis-of-hepatitis-c-virus-from-phase-2-and-3-clinical-trials-of-ledipasvir-sofosbuvir
#13
David Wyles, Hadas Dvory-Sobol, Evguenia S Brian Svarovskaia Doehle, Ross Martin, Nezam H Afdhal, Kris V Kowdley, Eric Lawitz, Diana M Brainard, Michael D Miller, Hongmei Mo, Edward J Gane
BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase 3 clinical trials, resulted in sustained viral suppression in 94%-99% of patients. Characterization of drug resistance in treatment failures may help inform retreatment options. METHODS: We performed NS5A and NS5B deep sequencing of HCV from patients infected with genotype (GT) 1 who participated in ledipasvir/sofosbuvir phase 2 and 3 clinical trials. RESULTS: Fifty-one of 2144 (2...
December 3, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27923518/the-impact-of-emerging-infectious-diseases-on-chinese-blood-safety
#14
REVIEW
Miao He, Jingxing Wang, Limin Chen, Jing Liu, Peibin Zeng
Emerging infectious diseases (EIDs) have always been one of the major threats to public health. Although the implementation of mandatory testing for 4 classical transfusion-transmitted infectious-human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis-has reduced the transfusion risk of these pathogens, the potential threat of various EID agents and their constantly evolving variants to blood safety in China is not fully understood. This review presents 9 representative EID agents that are autochthonous and epidemic nationally or regionally in China...
November 4, 2016: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/27922518/hepatitis-c-point-of-care-testing-in-vulnerable-populations-a-human-factors-study
#15
Donna M Zucker, Akshaya Shanmugam
One third of all hepatitis C virus (HCV) cases in the United States are incarcerated in jails and prisons. Hepatitis C virus testing is primarily accomplished through a clinical laboratory, yet point-of-care (POC) testing is less invasive and results are available in 20 minutes compared with up to 3 weeks. The purpose of this article was to describe the findings of a collaborative project between the Colleges of Engineering and Nursing at the University of Massachusetts Amherst in executing a human factors study for HCV antibody testing and screening...
November 2016: Gastroenterology Nursing: the Official Journal of the Society of Gastroenterology Nurses and Associates
https://www.readbyqxmd.com/read/27922182/retinoid-derivative-tp80-exhibits-anti-hepatitis-c-virus-activity-through-restoration-of-gi-gpx-expression
#16
Nguyen Bao Ngoc, Yukiko Okuno, Masahiko Ajiro, Kei Iida, Masatsugu Denawa, Makoto Yamamoto, Naoya Sakamoto, Hiroyuki Kagechika, Masatoshi Hagiwara
Hepatitis C virus (HCV) is a positive-sense single-stranded RNA virus with an estimated infection in ∼180 million people worldwide, and its chronic infection leads to development of cirrhosis and hepatocellular carcinoma. Although recent development of direct acting antiviral (DAA) compounds improved anti-HCV regimens, alternative therapeutic compounds are still demanded due to an expected emergence of escape mutants for those DAAs. In order to identify novel anti-HCV agents, we conducted chemical library screening for 2,086 compounds using HCV Rep-Feo reporter replicon in Huh7 hepatoma cells...
December 6, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27921633/healthcare-resources-are-inadequate-to-address-the-burden-of-illness-among-hiv-infected-male-prisoners-in-malaysia
#17
Joseph Bick, Gabriel Culbert, Haider A Al-Darraji, Clayton Koh, Veena Pillai, Adeeba Kamarulzaman, Frederick Altice
Purpose Criminalization of drug use in Malaysia has concentrated people who inject drugs (PWID) and people living with HIV into prisons where health services are minimal and HIV-related mortality is high. Few studies have comprehensively assessed the complex health needs of this population. The paper aims to discuss these issues. Design/methodology/approach From October 2012 through March 2013, 221 sequentially selected HIV-infected male prisoners underwent a comprehensive health assessment that included a structured history, physical examination, and clinically indicated diagnostic studies...
December 19, 2016: International Journal of Prisoner Health
https://www.readbyqxmd.com/read/27920651/use-of-direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-associated-oral-lichen-planus-a-case-report
#18
Kenji Misaka, Takashi Kishimoto, Yuji Kawahigashi, Michio Sata, Yumiko Nagao
Hepatitis C virus (HCV) is frequently associated with various extrahepatic manifestations such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one of the representative extrahepatic manifestations of HCV infection. Direct-acting antivirals (DAA) are highly effective and safe for the eradication of HCV. However, there is a lack of information regarding the association between HCV-associated OLP and interferon (IFN)-free DAA therapy. Herein, we present the case of a 60-year-old female who was diagnosed with OLP during routine periodontal treatment by a dentist...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920566/hcverso1-and-2-faldaprevir-with-deleobuvir-bi-207127-and-ribavirin-for-treatment-na%C3%A3-ve-patients-with-chronic-hepatitis-c-virus-genotype-1b-infection
#19
Christoph Sarrazin, Francesco Castelli, Pietro Andreone, Maria Buti, Massimo Colombo, Stanislas Pol, Filipe Calinas, Massimo Puoti, Antonio Olveira, Mitchell Shiffman, Jerry O Stern, George Kukolj, Michael Roehrle, Stella Aslanyan, Qiqi Deng, Richard Vinisko, Federico J Mensa, David R Nelson
The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (HCVerso2). Patients without cirrhosis were randomized to 16 weeks (Arm 1; n=208 HCVerso1, n=213 HCVerso2) or 24 weeks (Arm 2; n=211 in both studies) of faldaprevir + deleobuvir + ribavirin. Patients with compensated cirrhosis received open-label faldaprevir + deleobuvir + ribavirin for 24 weeks (Arm 3; n=51, n=72)...
2016: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/27920482/hepatitis-c-virus-therapy-with-peg-interferon-and-ribavirin-in-myanmar-a-resource-constrained-country
#20
Naomi Khaing Than Hlaing, Debolina Banerjee, Robert Mitrani, Soe Htet Arker, Kyaw San Win, Nyan Lin Tun, Zaw Thant, Khin Maung Win, K Rajender Reddy
AIM: To investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR). METHODS: This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a weight-based dose (15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response (RVR)...
November 21, 2016: World Journal of Gastroenterology: WJG
keyword
keyword
24818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"